| Product Description |
The
GenScript SARS-CoV-2 sVNT Kit (ELISA) - Multiplex VOC is a multiplex serology
assay that can detect the amount and inhibition rate of neutralizing antibodies
against variants of SARS-CoV-2 in parallel, especially against the Variants of
Concern (VOCs). The basic Multiplex VOC kit includes
SARS-CoV-2 RBD (Wild-Type). For
neutralizing antibodies against other variants, the assay can be
extended by adding alternate probes
(see V. EXTENSION PACKS). The assay detects any antibodies in serum or plasma
that neutralize the RBD-ACE2 interaction and the test is both species and
isotype independent.
The
kit can be used for large-scale serological investigations to study herd immunity
levels and to assess the level of neutralizing antibodies produced by the body
against wild-type and other variant strains following COVID-19 vaccination. |
| Kit Contents |
| Component |
Quantity/Size |
Part No. |
| Capture Plate |
1 plate |
D1-80 |
| Standard Stock |
1 vial (1 mL) |
D1-10 |
| Multiplex sVNT Probe RBD (WT) |
1 vial (20 μL) |
D1-20 |
| Enzyme Conjugate |
1 vial (20 μL) |
D1-30 |
| Assay Buffer |
2 bottles (15 mL/bottle) |
D1-90 |
| Sample Dilution Buffer |
1 bottle (60 mL) |
A1-60 |
| TMB Solution |
1 bottle (12 mL) |
A1-40 |
| 20× Wash Solution |
1 bottle (60 mL) |
A1-70 |
| Stop Solution |
1 bottle (6 mL) |
A1-50 |
| Plate Sealer |
2 pieces |
/ |
|
| Storage |
Store
at 2 - 8°C. Unopened kits are stable at 2 - 8°C until the expiration date
indicated on the kit label, and the opened kit is stable for up to 1 month from
the date of opening at 2°C to 8°C. |
| Assay Principle |
The GenScript
SARS-CoV-2 sVNT Kit (ELISA) - Multiplex VOC is a sVNT ELISA detection tool,
which mimics the virus neutralization process.
When the sample
and Multiplex sVNT Probe RBD are mixed and then added to the Capture Plate, the
mixture is captured on the plate. Enzyme Conjugate in this kit is HRP
conjugated human ACE2. The diluted Enzyme Conjugate is added to each well, and
then it is captured on the plate with unbound RBD and any RBD bound to non-neutralizing
antibodies, while the enzyme conjugate left in the supernatant are
removed during the washing process. After washing steps, TMB solution is added
and the color turns blue. The reaction is stopped by adding stop solution and
the color turns yellow which can be read at 450 nm by a microtiter plate
reader. The OD450 value is inversely proportional to the concentration of
neutralizing antibodies. |
| Background |
SARS-CoV-2
(Severe acute respiratory syndrome coronavirus 2) is a positive-sense single-stranded
RNA virus. SARS-CoV-2 contains glycosylated spike (S) protein, which is
composed of S1 subunit and S2 subunit. The S1 subunit contains a receptor
binding domain (RBD), which is responsible for recognizing the cell surface
receptor, angiotensin converting enzyme-2 (ACE2). Infection
with the SARS-CoV-2 virus initiates an immune response, which includes the
production of antibodies in the blood. Some secreted antibodies provide
protection against future infections from viruses, because they remain in the
circulatory system for months to years after infection and will bind quickly
and strongly to the pathogen to block cellular infiltration and replication.
These antibodies are named neutralizing antibodies.
During
the COVID-19 pandemic, a number of specific point mutations and combinations of
mutations emerged in the SARS-CoV-2 sequence, most of which were found in the
RBD region. The term variant of concern (VOC) is a category used during the
initial assessment of a newly emerged variant of a virus, containing
combinations of mutations that have been associated with a clinically or
epidemiologically significant phenotype. The previously circulating VOCs are
Omicron/B.1.1.529, Alpha/B.1.1.7. B.1.1.7, Beta/B.1.351, Gamma/P.1,
Delta/B.1.617.2 [1]. |
For research use only. Not intended for human and animal
therapeutic or diagnostic use.
